New Treatment Options in Advanced Squamous Cell Lung Cancer
Authors:
- 1 May 2019
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in American Society of Clinical Oncology Educational Book
- Vol. 39 (39) , e198-e206
Abstract
The past few years have witnessed a rapid shift in the treatments for patients with squamous cell lung cancers (SQCLCs) after the U.S. Food and Drug Administration approval of a number of immune checkpoint inhibitors as second-line therapies for patients with non–small cell lung cancers. These series of approvals marked the first substantial improvement in overall survival for patients with SQCLC in over a decade. Further gains have been made more recently with the incorporation of immune checkpoint inhibition in the first-line setting, either as monotherapy or in combination with chemotherapy. These advances have, however, exposed existing deficiencies in the management of this disease. Despite a deeper understanding of the genomic alterations that characterize SQCLCs and years of trial work targeting these alterations, personalized therapies remain out of hand. Future studies will continue to focus on identifying targeted approaches to expand the treatment options for our patients.Keywords
This publication has 43 references indexed in Scilit:
- Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialThe Lancet Oncology, 2013
- Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical ModelsClinical Cancer Research, 2012
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-SmokersCell, 2012
- Pathology of Lung CancerClinics in Chest Medicine, 2011
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung CancerScience Translational Medicine, 2010
- Development of Cell-Cycle Inhibitors for Cancer TherapyCurrent Oncology, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- PIK3CA mutation and amplification in human lung cancerPathology International, 2007
- A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor Performance Status and/or Are ElderlyJournal of Thoracic Oncology, 2007